GLM 1RA
Alternative Names: GLM-1RALatest Information Update: 20 Sep 2024
At a glance
- Originator GL PharmTech
- Class Antiulcers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastrointestinal ulcer
Most Recent Events
- 05 Sep 2024 Phase-I clinical trials in Gastrointestinal ulcer (unspecified route) (GL PharmTech pipeline, September 2024)